Bicara Therapeutics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the results of the 2026 Annual Meeting of Stockholders held by Bicara Therapeutics Inc. on June 9, 2026. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Global Market under the symbol BCAX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting. Approximately 85.25% of the 65,600,370 outstanding shares were present or represented.
- Proposal 1: Election of Directors
- Christopher Bowden, M.D.: Elected with 48,558,710 votes for and 5,145,418 votes withheld.
- Carolyn Ng, Ph.D.: Elected with 47,431,269 votes for and 6,272,859 votes withheld.
- Both directors were elected to Class II terms ending at the 2029 annual meeting.
- Proposal 2: Ratification of Independent Auditor
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Votes For: 55,914,602; Votes Against: 8,815; Votes Abstaining: 1,570.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The report is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the full composition of the Board of Directors following the election of Class II directors.
- Confirm the engagement letter terms with KPMG LLP for the 2026 fiscal year.
- Review the definitive proxy statement filed on April 27, 2026, for detailed background on the director nominees and auditor selection.